• FLEXcyte 96

  • FLEXcyte 96

  • FLEXcyte 96

  • FLEXcyte 96


2020 - Mechanobiology of in vitro assays: Tackling prevailing challanges in pre-clinical drug development

Icon FLEX    FLEXcyte 96 presentation (slide deck)  logo pdf (1.5 MB)

Dr. Matthias Gossmann
co-founder and CEO at InnoVitro, Germany

The 64th Annual Meeting of the Biophysical Society, San Diego, CA (USA)
Feb 15-19. 2020

Common systems for the quantification of cellular contraction rely on animal-based models, complex experimental setups or indirect approaches. Integration into standard lab procedures remains a challenge for current in vitro systems. The FLEXcyte 96 system has the potential to scale-up mechanical testing towards medium-throughput analyses. We show here that, using stem cell-derived cardiomyocytes, this system enables predictive recordings of contractile behaviour in the presence of well-known reference compounds.



FLEXcyte 96 Brochure

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.